Genmab A (GMAB) Net Margin (2018 - 2026)
Genmab A's (GMAB) quarterly Net Margin came in at 24.85% in Q2 2026, down 2411.0% on a YoY basis from 1.08% in Q2 2025, and down 96.08% quarter-over-quarter from 634.15% in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) Net Margin (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Net Margin for 9 consecutive years, with 24.85% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 2411.0% year-over-year to 24.85%; the trailing twelve-month figure through Jun 2026 stood at 197.12% (up 3937.0% YoY), and the FY2025 full-year result was 25.89%, down 1732.0% from the prior year.
- Net Margin fell to 24.85% in Q2 2026 per GMAB's latest filing, from 634.15% in the prior quarter.
- Across five years, Net Margin topped out at 740.7% in Q1 2025 and bottomed at 14.41% in Q2 2024.
- Historically, Net Margin has averaged 227.64% across 5 years, with a median of 78.72% in 2022.
- The sharpest annual moves came in 2025 and 2026: Net Margin jumped 22126 bps in 2025, then sank 10655 bps in 2026.
- Over 5 years, Net Margin stood at 78.72% in 2022, then plunged by 66 bps to 26.98% in 2023, then soared by 417 bps to 139.42% in 2024, then soared by 55 bps to 216.04% in 2025, then plunged by 88 bps to 24.85% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 24.85%, 634.15%, and 216.04% for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 30.23% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -539.31% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 31.16% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -20,152.98% |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 24.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.85% |
| Mar 31, 2026 | 634.15% |
| Sep 30, 2025 | 216.04% |
| Jun 30, 2025 | 48.96% |
| Mar 31, 2025 | 740.70% |
| Sep 30, 2024 | 139.42% |
| Jun 30, 2024 | 14.41% |
| Mar 31, 2024 | 519.44% |
| Dec 31, 2023 | 26.98% |
| Sep 30, 2023 | 60.39% |
| Jun 30, 2022 | 78.72% |
| Dec 31, 2021 | -1,019.02% |
| Sep 30, 2021 | 106.63% |
| Jun 30, 2021 | 72.21% |
| Dec 31, 2020 | 264.14% |
| Sep 30, 2020 | 1,071,751,740.14% |
| Jun 30, 2020 | 79.40% |
| Dec 31, 2019 | 1,203,365,384.62% |
| Sep 30, 2019 | 67.25% |
| Jun 30, 2019 | 14.34% |